ARTICLE | Company News
Zealand, Wyeth cardiovascular deal
May 1, 2003 7:00 AM UTC
WYE will co-develop ZP123 from Zealand (Glostrup, Denmark) to treat arrhythmias and other cardiovascular diseases. ZP123 peptide acts on gap junctions, which help maintain normal heart rhythm. The par...